Dichlorphenamide-13C6 (Synonyms: Diclofenamide-13C6) |
Catalog No.GC47210
One-Click Copy Product Info
|
An internal standard for the quantification of dichlorphenamide
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1391054-76-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Dichlorphenamide-13C6 is intended for use as an internal standard for the quantification of dichlorphenamide by GC- or LC-MS. Dichlorphenamide is a sulfonamide and an orally bioavailable carbonic anhydrase (CA) inhibitor (Kis = 1.20, 38, 50, and 50 nM for the human CA isoforms CAI, CAII, CAIX, and CAXII, respectively).1 It lowers intraocular pressure in rabbits when 50 µl of a 10% solution is applied topically to the eye.2 Dichlorphenamide rescues the potassium deficiency and prevents insulin-induced paralysis in a rat model of familial hypokalemic periodic paralysis when administered at a dose of 5.6 mg/kg per day for ten days.3 Formulations containing dichlorphenamide have been used in the treatment of glaucoma and primary periodic paralysis.
1.Brzozowski, Z., Slawi?ski, J., Innocenti, A., et al.Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XIIEur. J. Med. Chem.45(9)3656-3661(2010) 2.Lotti, V.J., Schmitt, C.J., and Gautheron, P.D.Topical ocular hypotensive activity and ocular penetration of dichlorphenamide sodium in rabbitsGraefes Arch. Clin. Exp. Ophthalmol.222(1)13-19(1984) 3.Tricarico, D., Mele, A., and Conte Camerino, D.Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channelsNeuromuscul. Disord.16(1)39-45(2006)
| Cas No. | 1391054-76-4 | SDF | |
| Synonymes | Diclofenamide-13C6 | ||
| Canonical SMILES | NS([13C]1=[13CH][13C](S(N)(=O)=O)=[13CH][13C](Cl)=[13C]1Cl)(=O)=O | ||
| Formula | [13C]6H6Cl2N2O4S2 | M.Wt | 311.1 |
| Solubility | Chloroform: slightly soluble,DMSO: slightly soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2144 mL | 16.072 mL | 32.144 mL |
| 5 mM | 642.9 μL | 3.2144 mL | 6.4288 mL |
| 10 mM | 321.4 μL | 1.6072 mL | 3.2144 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)